| 前收市價 | 37.42 |
| 開市 | 37.40 |
| 買盤 | 36.42 x 37000 |
| 賣出價 | 36.49 x 43000 |
| 今日波幅 | 36.42 - 37.15 |
| 52 週波幅 | 36.42 - 59.00 |
| 成交量 | |
| 平均成交量 | 5,106 |
| 市值 | 73.979B |
| Beta 值 (5 年，每月) | 0.44 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.87 |
| 業績公佈日 | 2024年4月25日 |
| 遠期股息及收益率 | 2.23 (5.97%) |
| 除息日 | 2024年7月05日 |
| 1 年預測目標價 | 無 |
ReutersBristol Myers to pay $2.7 million to settle Israel anti-competition charges
Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, Israel's Competition Authority said on Monday. The anti-trust agency said that Bristol and Neopharm Scientific, the Israeli distributor of Imnovid - used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma - declined a request by KS Kim International for drug samples to make a copycat version of Imnovid.
Motley FoolIs Bristol Myers Squibb Stock a Buy?
Does Bristol Myers have the potential to be a market-beating stock?
BenzingaNovo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO). Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. Related: FDA Appr
